(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 150.15% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.41%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.65%.
Liquidia's revenue in 2025 is $15,610,000.On average, 5 Wall Street analysts forecast LQDA's revenue for 2025 to be $3,937,464,882, with the lowest LQDA revenue forecast at $2,287,727,866, and the highest LQDA revenue forecast at $5,645,262,621. On average, 5 Wall Street analysts forecast LQDA's revenue for 2026 to be $12,012,983,438, with the lowest LQDA revenue forecast at $4,291,076,685, and the highest LQDA revenue forecast at $16,664,950,675.
In 2027, LQDA is forecast to generate $20,799,788,157 in revenue, with the lowest revenue forecast at $7,817,884,682 and the highest revenue forecast at $28,429,440,994.